RecruitingNCT05987631

Predictors of Weight Loss and Metabolic Health After Bariatric Surgery

Preoperative Predictors of Weight Loss and Improved Metabolic Health After Bariatric Surgery

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Enrollment

1,200 participants

Start Date

Jan 19, 2023

Study Type

OBSERVATIONAL

Conditions

Obesity, Morbid Bariatric Surgery Candidate Insulin Sensitivity Feeding Behavior

Summary

In this prospective study the investigators aim to identify preoperative predictors of improvement of metabolic health and weight loss after bariatric surgery focusing on inflammation, insulin sensitivity (in a subgroup of patients), glucoregulatory determinants, psychological traits, feeding behavior characteristics and cardiorespiratory fitness

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria11

Ability to provide informed consent
Patient is ≥ 18 and ≤ 75 years old
BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity
Scheduled for primary bariatric procedure: Roux-en-Y gastric bypass (RYGB) or Sleeve Gastrectomy (SG)
Stable weight 3 months prior to inclusion weight (<10% change in body weight for 3 months prior to assessments)
Ability to provide informed consent
Patient is ≥ 18 and ≤ 75 years old
BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity
Patients scheduled for RYGB
Patients who are insulin resistant (impaired fasting glucose (> 5.6 mmol/L) or fasting insulin > 74 pmol/L)
Postmenopausal women (to prevent bias due to the effect of sex hormones on insulin sensitivity)

Exclusion Criteria6

Any actual medical condition except for obesity related health issues or well treated hypothyroidism
Pregnancy anticipated in the first two years following surgery
A potential subject who meet the following criteria will be excluded from participation in the subgroup of this study:
Coagulation disorders and/or use anticoagulants
Use of any medication except for statins, antihypertensives (except for Angiotensine converting enzyme (ACE)- or angiotensin receptor blockers) and thyroid hormone
Diabetes mellitus type 2